Last week I had the honor of presenting Osteoboost, our soon-to-launch FDA-cleared precision vibration therapy medical device, at the 2024 Hitlab Women’s Health Tech event held on October 11. And I’m thrilled to report that Osteoboost won both first place in the seed-stage category and the event’s People’s Choice Award!…
Read more
Almost four years ago, I had my second dexa scan and got the news that I have learned is typical: in the five years after menopause, my bone density went from normal to osteopenia. I lost 13% of my bone density in my spine. I got a weirdly chipper note…
Read more
BHT closes oversubscribed financing round, adds new investors to revolutionize low bone density treatments Redwood City, CA – March 4, 2024 – Bone Health Technologies (BHT), a health technology innovator developing breakthrough non-invasive solutions for bone health, today announced the company has raised a new $5 million funding round from…
Read more
Catch up on the latest news coverage of Bone Health Technologies and the breakthrough Osteoboost belt for osteopenia treatment.
Redwood City, CA – January 18, 2024 – Bone Health Technologies today announced that the U.S. Food and Drug Administration (FDA) has granted clearance for OsteoboostTM, the first non-pharmacological device-based prescription treatment for postmenopausal women diagnosed with osteopenia (low bone density). Osteoboost is a wearable belt device, worn on the…
Read more
First Device to Demonstrate Bone Strength Benefit in Clinical Trial REDWOOD CITY, CA (DEC, 2023)– Bone Health Technologies (BHT), a leading innovator in health technologies to improve bone health, has been granted its fourth patent to further its commercialization of the Osteoboost device. Osteoboost has been shown in clinical trials…
Read more
Osteoboost Reduced the Loss of Vertebral Bone Strength by 83% in One Year for Per Protocol Participants Vancouver, BC, Canada (October 13, 2023)– Bone Health Technologies (BHT), a leading innovator in health technologies to improve bone health, is presenting top-line results from its pivotal trial for the Osteoboost at ASBMR…
Read more
